MET and neoplasm: Pharmacodynamically, HVS at 10 mg/kg, 3×/week, i.p., significantly inhibited the phosphorylation of c-Met kinase in human breast MDA-MB-231 xenograft tumors when compared to the vehicle treated control group, as shown by Western blot analysis of the isolated tumor tissues, without any change in total c-Met levels (Figure 10D).